FTC seeks Supreme Court review in K-Dur case
Executive Summary
An appeals court's ruling that a Schering-Plough/Upsher-Smith settlement over generic K-Dur was not anticompetitive "could seriously impede" FTC's law enforcement efforts, the commission says in an Aug. 29 petition for certiorari to the U.S. Supreme Court. FTC seeks review of an Atlanta-based appeals court's March 8 ruling, which stated that the commission should consider the potential exclusionary scope of a brand company's patent when evaluating brand/generic settlements (1"The Pink Sheet" March 14, 2005, p. 31)...You may also be interested in...
Brand/Generic Settlements Not Necessarily Illegal, DoJ Tells Supreme Court
Payments to generic companies to settle patent challenges under the Hatch-Waxman Act are not necessarily violations of antitrust law, the Office of the Solicitor General says in an amicus curiae brief to the U.S. Supreme Court
FTC Loses K-Dur Antitrust Case; Failure To Consider Schering Patent Cited
The Federal Trade Commission should consider the potential exclusionary scope of a brand-name drug company's patents when evaluating whether a settlement with a generic company is anticompetitive, a federal appeals court ruled March 8
Cybersecurity: Guidance Docs To Come, But Legacy Devices Still A Challenge
Increasing savvy around cybersecurity issues is driving regulators and trade groups to update their approach to the area, speakers from the US FDA and the American Medical Association said at this week’s FDA/CMS Summit.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: